ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Netherlands Cancer Institute at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Netherlands Cancer Institute takes part in 36 sessions at ESMO 2026 in Madrid. Its program focuses on immunotherapy and treatment decisions across cancer types, including breast cancer and melanoma. It examines whether immune-based treatment can help preserve organs in skin cancer and how biomarkers can guide treatment.
| Organization | ESMO 2026 Attendance |
|---|---|
Netherlands Cancer Institute Amsterdam, Netherlands | |
Cancer research institute with its own cancer hospital in Amsterdam, Netherlands. | Poster Fri Oct 23 13:00–15:00 A phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: PRIAM Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Clinical implementation of a robust IFN-gamma gene signature pipeline for treatment stratification in stage III melanoma Melanoma & skin cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Chair Fri Oct 23 13:30–15:00 Poster Fri Oct 23 15:15–16:00 Lung cancer subtyping using cell-free DNA fragmentomes and protein biomarkers Lung & thoracic cancersBiomarkers & precision oncology Chair Fri Oct 23 16:15–17:45 Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Talk Fri Oct 23 16:45–17:00 Tumor agnostic drug repurposing trials: Boost or brake? Biomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Chair Sat Oct 24 10:15–11:30 Multidisciplinary insights for effective care in gynaecological sarcomas Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 10:15–10:30 Talk Sat Oct 24 10:15–10:35 Talk Sat Oct 24 10:15–10:35 Treating for two: Immunotherapy, targeted therapy, and other treatments in pregnancy Melanoma & skin cancers Talk Sat Oct 24 10:50–11:05 Local treatment: Surgery (LMS/HGUS/ESS) Sarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Innate lymphocytes kickstart immunotherapy responses in colon cancer Gastrointestinal cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma – MARIANE Melanoma & skin cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Week 6 interferon-gamma signature identifies melanoma patients at high risk of recurrence to neoadjuvant immunotherapy Melanoma & skin cancersBiomarkers & precision oncology Talk Sat Oct 24 12:19–12:26 Talk Sat Oct 24 14:45–15:05 Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 17:06–17:18 Invited Discussant LBA2 Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Chair Sun Oct 25 10:15–11:45 Talk Sun Oct 25 10:35–10:55 Novel immunotherapy; CAR-T, Bispecific antibodies, New ICIs Genitourinary cancers Abstract Sun Oct 25 10:52–10:57 Abstract Sun Oct 25 11:14–11:19 Abstract Sun Oct 25 11:33–11:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Neoadjuvant nivolumab plus relatlimab or nivolumab plus IL-8 in pMMR colon cancer Gastrointestinal cancers Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Validation of deep learning-based TIL assessment in young patients with node-negative HER2-positive breast cancer Breast cancerBiomarkers & precision oncology Chair Sun Oct 25 16:30–18:00 Peri-operative management of urothelial cancer Genitourinary cancers Chair Sun Oct 25 16:30–18:00 Abstract Mon Oct 26 09:29–09:34 3724RO - Patient reported outcomes (PROs) with varegacestat versus placebo (PBO) in progressing desmoid tumors: Results from RINGSIDE Part B Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 10:20–10:25 4250RO - High affinity FcγR3A germline SNP impairs outcome upon anti-PD1 in melanoma Biomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Health-related quality of life in intra-abdominal and retroperitoneal sarcoma patients: An international multicentre study Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersNursing & supportive care Chair Mon Oct 26 14:45–16:15 Proffered paper 2: Basic science and translation research Biomarkers & precision oncology Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 14:55–15:07 Talk Mon Oct 26 15:25–15:45 Abstract Mon Oct 26 15:49–16:01 Invited Discussant 4240O and 4242O Biomarkers & precision oncology |
Find decision makers at Netherlands Cancer Institute
Tell us what you sell and we’ll find the people at Netherlands Cancer Institute most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction